NYMOX PHARMACEUTICAL CORPORATION Adjustments For Finance Income Cost
NYMOX PHARMACEUTICAL CORPORATION (NYMXF) reported Adjustments For Finance Income Cost of -$209.00 thousand for the 12-month period ending 2024-12-31, per its 20-F filed 2025-06-03.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:AdjustmentsForFinanceIncomeCost · last filed 2025-06-03
| Period end | Adjustments For Finance Income Cost 12 month |
|---|---|
| 2024-12-31 | -$209.00K 20-F · filed 2025-06-03 |
| 2023-12-31 | -$54.00K 20-F · filed 2025-06-03 |
| 2022-12-31 | -$37.00K 20-F · filed 2025-06-03 |
| 2021-12-31 | -$33.00K 20-F · filed 2024-08-29 |
| 2020-12-31 | -$18.00K 20-F · filed 2023-05-02 |
| 2019-12-31 | $163.00K 20-F · filed 2022-03-30 |
| 2018-12-31 | $47.00K 20-F · filed 2021-03-29 |
| 2017-12-31 | -$194.00K 20-F · filed 2020-03-30 |
| 2016-12-31 | -$240.00K 20-F · filed 2019-03-29 |